Emmaus Life Sciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
OQB
SCHEDULE 13G/A: Dr. Seah H. Lim Amends Significant Stake in Emmaus Life Sciences, Holding 6.5% of Common Stock
Dr. Seah H. Lim has filed an amended Schedule 13G, disclosing a beneficial ownership of 4,147,426 shares, representing 6.5% of Emmaus Life Sciences, Inc.'s common stock as of December 31, 2024.